A clinical oncology company has claimed that a new pill tested in the United States for the treatment of late-stage pancreatic cancer may significantly improve survival rates compared to traditional chemotherapy.
According to the study, patients with pancreatic cancer - one of the most aggressive and deadly forms of cancer - who took a once-daily drug called Drexonrasib showed up to a 60% lower risk of death compared to those receiving standard chemotherapy.
The findings emerged from a Phase 3 clinical trial involving 500 participants. Researchers suggest that the drug could represent a more effective and less physically taxing treatment option for patients suffering from advanced pancreatic cancer.
Professor Brian Wolpin of Harvard Medical School stated that the drug could offer new hope even for patients whose cancer continues to progress despite chemotherapy treatment.
